Cirsimaritin

Cirsimaritin

SCHEMBL1663486

COc1cc2oc(-c3ccc(O)cc3)cc(=O)c2c(O)c1OC

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 5/20 1.00
MAPT P10636 5/20 1.00
KDM4E B2RXH2 4/20 1.00
ADORA3 P0DMS8 1/20 1.00
FLT3 P36888 4/20 0.84
CYP1A1 P04798 3/20 0.80
CYP1B1 Q16678 3/20 0.80
OPRD1 P41143 2/20 0.80
CYP1A2 P05177 1/20 0.80
MEN1 O00255 4/20 0.79
KMT2A Q03164 4/20 0.79
NPC1 O15118 2/20 0.79
RAB9A P51151 2/20 0.79
GABRP O00591 1/20 0.79
GABRD O14764 1/20 0.79
PIM1 P11309 1/20 0.79
GABRA1 P14867 1/20 0.79
GABRB1 P18505 1/20 0.79
GABRG2 P18507 1/20 0.79
GABRB3 P28472 1/20 0.79

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Cirsimaritin SCHEMBL29459674 1.00 POLB (1.00) POLBMAPTKDM4EADORA3FLT3
SCHEMBL735537 0.92 MAPT (0.85) POLBMAPTKDM4EADORA3FLT3
Salvigenin SCHEMBL1427018 0.91 FLT3 (1.00) POLBMAPTKDM4EADORA3FLT3
SCHEMBL28040107 0.91 POLB (1.00) POLBMAPTKDM4EADORA3FLT3
SCHEMBL17258303 0.90 POLB (0.82) POLBMAPTKDM4EADORA3FLT3
Mosloflavone SCHEMBL971985 0.90 KDM4E (0.81) POLBMAPTKDM4EADORA3FLT3
Mosloflavone SCHEMBL29477310 0.90 KDM4E (0.81) POLBMAPTKDM4EADORA3FLT3
SCHEMBL739122 0.90 POLB (0.83) POLBMAPTKDM4EADORA3FLT3
SCHEMBL34468184 0.89 CYP1B1 (1.00) POLBMAPTKDM4EADORA3FLT3
SCHEMBL31238120 0.89 CYP1B1 (1.00) POLBMAPTKDM4EADORA3FLT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 417 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4698662-A2 REGULATABLE CONTROLLED EXPRESSION OF A TRANSGENE IN PRIMATES AskBio Inc. (US) 2026-02-25 EP claimed
WO-2025199801-A1 COMPOSITION FOR TREATING RENAL DYSFUNCTION-ASSOCIATED DIABETIC FOOT ULCERS IN SUBJECT 合一生技股份有限公司 2025-10-02 WO claimed
EP-4595768-A2 PET FOOD COMPOSITIONS Hill's Pet Nutrition, Inc. (US) 2025-08-06 EP claimed
EP-4543425-A1 PLECTRANTHUS AMBOINICUS EXTRACT FOR USE IN ALLEVIATION OF RADIATION-INDUCED SKIN DISORDERS Oneness Biotech Co., Ltd. (TW) 2025-04-30 EP claimed
EP-3397069-B1 PET FOOD COMPOSITIONS HILLS PET NUTRITION INC (US) 2025-04-16 EP claimed
EP-4531841-A1 PLECTRANTHUS AMBOINICUS EXTRACT FOR USE IN INHIBITING IMMUNE RESPONSES Oneness Biotech Co., Ltd. (TW) 2025-04-09 EP claimed
WO-2024220449-A9 REGULATABLE CONTROLLED EXPRESSION OF A TRANSGENE IN PRIMATES AskBio Inc. (US) 2025-04-03 WO claimed
US-20250051551-A1 IMPROVED POLYMER COMPOSITES WARNER BABCOCK INSTITUTE FOR GREEN CHEMISTRY, LLC (US) 2025-02-13 US claimed
US-20250011393-A1 FLAVONOID-COLLAGEN CROSSLINKED ANTIOXIDANT HYDROGEL NORTH CAROLINA STATE UNIVERSITY 2025-01-09 US claimed
US-20240390504-A1 MULTIFUNCTIONAL CONJUGATES E P O S IASIS RES AND DEVELOPMENT LIMITED (CY) 2024-11-28 US claimed
US-20140017341-A1 COMPOSITION AND METHOD FOR TREATING FAT TISSUES AND INFLAMMATORY PROCESSES GOURLAOUEN BRIGITTE (FR) 2014-01-16 US claimed
CN-103420967-A Preparation method for marina thistle flavin NANJING BIAOKE BIO TECHNOLOGY CO LTD 2013-12-04 CN claimed
CN-103127215-A Extract of joss-stick having anti-arthritic activity ONENESS BIOTECH CO 2013-06-05 CN claimed
US-20110160136-A1 POLYPHENOLS FOR THE TREATMENT OF CARTILAGE DISORDERS NESTEC S.A. (CH) 2011-06-30 US claimed
EP-2247290-A1 POLYPHENOLS FOR THE TREATMENT OF CARTILAGE DISORDERS Nestec S.A. (CH) 2010-11-10 EP claimed
WO-2009106125-A1 POLYPHENOLS FOR THE TREATMENT OF CARTILAGE DISORDERS NESTEC S.A. (CH) 2009-09-03 WO claimed
US-20060115502-A1 Cosmetic composition based on cirsimarin GATTEFOSSE SAS (FR) 2006-06-01 US claimed
US-6471973-B2 DRUGS, COSMETICS, DIETETICS, AGRICULTURE COLETICA (FR) 2002-10-29 US claimed
US-6451837-B1 Neuroprotective effects of mitogen-activated protein kinase (MAPK) cascade inhibitors BASKYS ANDRIUS (US) 2002-09-17 US claimed
US-20010031735-A1 Flavonoide esters and their use notably in cosmetics COLETICA (FR) 2001-10-18 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110160136-A1 POLYPHENOLS FOR THE TREATMENT OF CARTILAGE DISORDERS COL2A1, MTPN, CPT1B POLB 1729/4885MAPT 2938/4885KDM4E 535/4885
US-20010031735-A1 Flavonoide esters and their use notably in cosmetics TYR, MITF, CYP2F1 POLB 3446/4885MAPT 2248/4885KDM4E 512/4885
US-20060115502-A1 Cosmetic composition based on cirsimarin PLIN1, PLIN3, PLIN5 POLB 1970/4885MAPT 4178/4885KDM4E 3754/4885
US-20240390504-A1 MULTIFUNCTIONAL CONJUGATES MKI67, ACP3, CD44 POLB 2600/4885MAPT 3085/4885KDM4E 2798/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.